Navigation Links
Cleveland Clinic researchers identify urgent need for Alzheimer's drug development

THURSDAY, July 3, 2014, Las Vegas: Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer's disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments. The paper, "Alzheimer's Disease Drug Development Pipeline: Few Candidates, Frequent Failures," was published today in the journal Alzheimer's Research & Therapy.

A comprehensive look at all clinical trials underway shows:

  • There are relatively few drugs in development for Alzheimer's disease.
  • The failure rate for AD drug development is 99.6 percent for the decade 2002-2012.
  • The number of drugs has been declining since 2009.

"Our goal was to examine historical trends to help understand why Alzheimer's disease treatment development efforts so often fail," said Jeffrey L. Cummings, M.D., ScD, Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. "With an estimated 44 million people living worldwide with the condition, the study shows that the Alzheimer's disease drug development ecosystem needs more support given the magnitude of the problem."

Using the advanced search mechanisms of, a government website that records all ongoing clinical trials, Dr. Cummings, along with Kate Zhong, M.D., Senior Director of Clinical Research and Development, and Touro University medical student Travis Morstorf, constructed a comprehensive analysis to examine all trials since 2002.

"By analyzing both completed as well as on-going trials and currently active compounds, we were able to provide insight into longitudinal trends in drug development," said Dr. Zhong. "What we found was that the investment in AD drugs and therapies is relatively low compared to the challenge posed by the disease. The pipeline is almost dry."

This comprehensive analysis illustrates the high rate of failure of compounds and the need for a constant supply of new drugs or a higher focus on repurposing, which can be assessed for efficacy in AD. With AD more expensive to the U.S. economy than cardiovascular disease or cancer, the Lou Ruvo Center for Brain Health research team believes the system of AD drugs must be supported, grown and coordinated to improve the success rate and development of new therapies.

In order to accelerate the drug development process and reduce the need to constantly invent new drugs, researchers note the need for more repositioning studies, which involve studying an already-approved drug in a new use or condition. For example, researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health are leading a landmark Phase IIa clinical trial to determine if bexarotene (Targretin), a drug currently FDA approved to treat skin cancer, can remove a protein build-up in the brains of Alzheimer's patients, as it did in a recent animal study.


Contact: Megan Pruce
Cleveland Clinic

Related medicine news :

1. Cleveland Clinic selected to participate in National MDS Clinical Research Consortium
2. Cleveland Clinic researchers discover molecule that may prevent atherosclerosis
3. Cleveland Clinic Florida receives approval for transplant programs at Weston Facilities
4. Cleveland Clinic researchers investigating potential drug for treatment of Alzheimers disease
5. Cleveland Clinic study shows vitamin E may decrease cancer risk in Cowden syndrome patients
6. University Hospitals & Philips Healthcare to showcase imaging technology at Cleveland Medical Mart
7. Cleveland Clinic researcher identifies 2 new genetic mutations associated with Cowden syndrome
8. Redskins Quarterback & Lynx Shreds Athlete Kirk Cousins will Start Today vs. Cleveland Browns for Injured RG3
9. Cleveland Clinic researcher receives grant to fund autism research
10. Cleveland Clinic study shows bariatric surgery restores pancreatic function by targeting belly fat
11. Vein Expert in Winston-Salem, NC Participates in Elite Cleveland Clinic Seminar
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... The Museum of Science & ... a new era of publicly accessible automated technology. Now, by popular demand, the ... guests an up-close look at the shuttle at MOSI’s main entrance. This experience ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally deals ... So why is it a national news story when Donald Trump makes disparaging remarks ... because appearances count more than anyone wants to admit when it comes to how ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... course in Dallas, TX, on January 29 and 30, 2016. The course welcomes ... functions of their practices, to learn how to better succeed in the modern ...
(Date:11/30/2015)... Georgia (PRWEB) , ... November 30, 2015 , ... ... of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant ... at Georgia State University. , Their study showed that small molecule analogs that ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies specializes in orthodontics ... visit Dr. Margulies to experience the best available orthodontic experience in the area. ... Top Dentist"! , Orthodontics is the branch of dentistry that specializes in the diagnosis, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Asia,s largest exhibition and conference dedicated to the Medical ...  - 22 nd April 2016. --> --> ... --> -->   --> ... aging population and the government back up, the Medical Device is one of ... States . With the aging population and the government back up, the ...
(Date:11/30/2015)... 30, 2015 Nevro Corp. (NYSE: NVRO ), ... solutions for the treatment of chronic pain, today announced that ... Patent and Trademark Office (USPTO) has denied instituting an ... (the ,102 patent).  --> ... Scientific Corporation filed two petitions challenging the validity of certain ...
(Date:11/30/2015)... , Nov. 30, 2015 ... of the "Orphan Drugs Market 2015-2019" ... ) has announced the addition of the ... offering. --> Research and Markets ( ... "Orphan Drugs Market 2015-2019" report to ...
Breaking Medicine Technology: